Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Pneumococcal serotype determines growth and capsule size in human cerebrospinal fluid.

Müller A, Salmen A, Aebi S, de Gouveia L, von Gottberg A, Hathaway LJ.

BMC Microbiol. 2020 Jan 20;20(1):16. doi: 10.1186/s12866-020-1700-7.

2.

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators.

Br J Cancer. 2020 Jan 16. doi: 10.1038/s41416-019-0709-x. [Epub ahead of print]

PMID:
31949268
3.

Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.

Hamzic S, Kummer D, Froehlich TK, Joerger M, Aebi S, Palles C, Thomlinson I, Meulendijks D, Schellens JHM, García-González X, López-Fernández LA, Amstutz U, Largiadèr CR.

Pharmacol Res. 2020 Feb;152:104594. doi: 10.1016/j.phrs.2019.104594. Epub 2019 Dec 12.

4.

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.

Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T.

BMC Cancer. 2019 Sep 10;19(1):902. doi: 10.1186/s12885-019-6105-3.

5.

Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.

Bustamante Eduardo M, Popovici V, Imboden S, Aebi S, Ballabio N, Altermatt HJ, Günthert A, Jaggi R.

BMC Cancer. 2019 Jun 7;19(1):549. doi: 10.1186/s12885-019-5752-8.

6.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators.

Br J Cancer. 2019 May;120(10):959-967. doi: 10.1038/s41416-019-0435-4. Epub 2019 Apr 10. Erratum in: Br J Cancer. 2020 Jan 16;:.

PMID:
30967649
7.

The Indoor-Air Microbiota of Pig Farms Drives the Composition of the Pig Farmers' Nasal Microbiota in a Season-Dependent and Farm-Specific Manner.

Kraemer JG, Aebi S, Oppliger A, Hilty M.

Appl Environ Microbiol. 2019 Apr 18;85(9). pii: e03038-18. doi: 10.1128/AEM.03038-18. Print 2019 May 1.

8.

Peptide Ligands of AmiA, AliA, and AliB Proteins Determine Pneumococcal Phenotype.

Nasher F, Aguilar F, Aebi S, Hermans PWM, Heller M, Hathaway LJ.

Front Microbiol. 2018 Dec 5;9:3013. doi: 10.3389/fmicb.2018.03013. eCollection 2018.

9.

Letter comments on EJC published article: Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2-positive breast carcinomatous meningitis.

Hofer S, Aebi S.

Eur J Cancer. 2018 Nov;103:279-280. doi: 10.1016/j.ejca.2018.07.317. Epub 2018 Sep 27. No abstract available.

PMID:
30270111
10.

Angiosarcoma of the scalp responding to nivolumab: a case report.

Hofer S, Zeidler K, Schipf A, Kempf W, Zimmermann D, Aebi S.

Br J Dermatol. 2018 Aug;179(2):530-531. doi: 10.1111/bjd.16698. Epub 2018 Jun 13. No abstract available.

PMID:
29700818
11.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Paterson AHG, Rimawi MF, Láng I, Baena-Cañada JM, Thürlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; International Breast Cancer Study Group; NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group; Breast International Group.

J Clin Oncol. 2018 Apr 10;36(11):1073-1079. doi: 10.1200/JCO.2017.76.5719. Epub 2018 Feb 14.

12.

Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases.

Blum V, Müller B, Hofer S, Pardo E, Zeidler K, Diebold J, Strobel K, Brand C, Aebi S, Gautschi O.

Eur J Dermatol. 2018 Feb 1;28(1):78-81. doi: 10.1684/ejd.2017.3209.

PMID:
29336323
13.

Influence of Pig Farming on the Human Nasal Microbiota: Key Role of Airborne Microbial Communities

Kraemer JG, Ramette A, Aebi S, Oppliger A, Hilty M.

Appl Environ Microbiol. 2018 Mar 1;84(6). pii: e02470-17. doi: 10.1128/AEM.02470-17.

14.

Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.

Schwegler C, Kaufmann D, Pfeiffer D, Aebi S, Diebold J, Gautschi O.

Virchows Arch. 2018 Apr;472(4):581-588. doi: 10.1007/s00428-017-2268-y. Epub 2017 Dec 2.

PMID:
29198034
15.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
16.

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH.

Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651.

17.

Influence of the pneumococcal conjugate vaccines on the temporal variation of pneumococcal carriage and the nasal microbiota in healthy infants: a longitudinal analysis of a case-control study.

Mika M, Maurer J, Korten I, Allemann A, Aebi S, Brugger SD, Qi W, Frey U, Latzin P, Hilty M.

Microbiome. 2017 Jul 24;5(1):85. doi: 10.1186/s40168-017-0302-6.

18.

A Vexing CA 125 Raise in a Patient with Pleural Effusion and Ovarian Cancer.

Hofer S, Suter T, Aebi S.

Respiration. 2017;94(3):312. doi: 10.1159/000478532. Epub 2017 Jul 8. No abstract available.

19.

Spotlight on pomalidomide: could less be more?

Zander T, Aebi S, Pabst T, Renner C, Driessen C.

Leukemia. 2017 Sep;31(9):1987-1989. doi: 10.1038/leu.2017.156. Epub 2017 May 22. No abstract available.

20.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.

21.

Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.

Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, Amstutz U, Largiader CR.

Clin Pharmacol Ther. 2017 Nov;102(5):796-804. doi: 10.1002/cpt.641. Epub 2017 May 30.

PMID:
28139840
22.

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.

Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622.

23.

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; Swiss Group for Clinical Cancer Research.

J Thorac Oncol. 2016 Nov;11(11):1846-1855. doi: 10.1016/j.jtho.2016.05.032. Epub 2016 Jun 14.

24.

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.

Wapnir IL, Gelber S, Anderson SJ, Mamounas EP, Robidoux A, Martín M, Nortier JW, Geyer CE Jr, Paterson AH, Láng I, Price KN, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; CALOR trial investigators.

Ann Surg Oncol. 2017 Feb;24(2):398-406. doi: 10.1245/s10434-016-5571-y. Epub 2016 Sep 23.

25.

Response to Pembrolizumab in a Patient with Relapsing Thymoma.

Zander T, Aebi S, Rast AC, Zander A, Winterhalder R, Brand C, Diebold J, Gautschi O.

J Thorac Oncol. 2016 Dec;11(12):e147-e149. doi: 10.1016/j.jtho.2016.07.018. Epub 2016 Aug 4. No abstract available.

26.

Clinical Streptococcus pneumoniae isolates induce differing CXCL8 responses from human nasopharyngeal epithelial cells which are reduced by liposomes.

Baumgartner D, Aebi S, Grandgirard D, Leib SL, Draeger A, Babiychuk E, Hathaway LJ.

BMC Microbiol. 2016 Jul 19;16(1):154. doi: 10.1186/s12866-016-0777-5.

27.

The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.

Hamzic S, Wenger N, Froehlich TK, Joerger M, Aebi S, Largiadèr CR, Amstutz U.

Pharmacogenomics J. 2017 Jul;17(4):319-324. doi: 10.1038/tpj.2016.23. Epub 2016 Mar 22.

PMID:
27001120
28.

[Male Breast Cancer: What is Different?].

Niederberger P, Bucher S, Aebi S.

Praxis (Bern 1994). 2016 Feb 3;105(3):147-51. doi: 10.1024/1661-8157/a002250. Review. German.

PMID:
26837323
29.

Successful AZD9291 Therapy Based on Circulating T790M.

Gautschi O, Aebi S, Heukamp LC.

J Thorac Oncol. 2015 Dec;10(12):e122-3. doi: 10.1097/JTO.0000000000000676. No abstract available.

30.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).

Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S.

Br J Cancer. 2015 Dec 22;113(12):1747. doi: 10.1038/bjc.2015.458. No abstract available.

31.

The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06).

Strasser F, Blum D, von Moos R, Cathomas R, Ribi K, Aebi S, Betticher D, Hayoz S, Klingbiel D, Brauchli P, Haefner M, Mauri S, Kaasa S, Koeberle D; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2016 Feb;27(2):324-32. doi: 10.1093/annonc/mdv576. Epub 2015 Dec 8.

32.

Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.

Gautschi O, Stadelmann C, Aebersold-Keller F, König K, Büttner R, Heukamp LC, Betticher D, Baumann C, Buser K, Calderoni A, Casty A, DʼAddario G, Irlé C, Mamot C, Morant R, Trojan A, Pellicioli E, Jehle-Schwertfeger S, Aebi S, Diebold J.

Oncol Res Treat. 2015;38(11):560-9. doi: 10.1159/000441367. Epub 2015 Oct 21.

PMID:
26599269
33.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).

Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S.

Br J Cancer. 2015 Sep 1;113(5):716-21. doi: 10.1038/bjc.2015.279. Epub 2015 Aug 27. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1747.

34.

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.

Kummer D, Froehlich TK, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr CR.

Pharmacogenomics. 2015;16(12):1367-77. doi: 10.2217/pgs.15.81. Epub 2015 Aug 5.

PMID:
26244261
35.

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

Weiler D, Diebold J, Strobel K, Aebi S, Gautschi O.

J Thorac Oncol. 2015 Apr;10(4):e16-7. doi: 10.1097/JTO.0000000000000424. No abstract available.

36.

Dynamics of the nasal microbiota in infancy: a prospective cohort study.

Mika M, Mack I, Korten I, Qi W, Aebi S, Frey U, Latzin P, Hilty M.

J Allergy Clin Immunol. 2015 Apr;135(4):905-12.e11. doi: 10.1016/j.jaci.2014.12.1909. Epub 2015 Jan 27.

37.

Complement activation and rituximab distribution in CNS NHL--letter.

Hofer S, Mengele K, Schmitt M, Pestalozzi B, Aebi S.

Clin Cancer Res. 2015 Jan 15;21(2):490. doi: 10.1158/1078-0432.CCR-14-0939. No abstract available.

38.

Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.

Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kühn T, Lippman ME, Lucci A, Piccart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, Wapnir IL, White JR, Smidt ML.

J Natl Cancer Inst. 2014 Nov 7;106(12). pii: dju288. doi: 10.1093/jnci/dju288. Print 2014 Dec.

39.

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.

Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadèr CR.

Int J Cancer. 2015 Feb 1;136(3):730-9. doi: 10.1002/ijc.29025. Epub 2014 Jun 27.

40.

First international consensus guidelines for breast cancer in young women (BCY1).

Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA Jr, Costa A, Delaloge S, Freilich G, Gentilini OD, Harbeck N, Kelly CM, Loibl S, Meirow D, Peccatori F, Kaufmann B, Cardoso F.

Breast. 2014 Jun;23(3):209-20. doi: 10.1016/j.breast.2014.03.011. Epub 2014 Apr 24.

PMID:
24767882
41.

Streptococcus pneumoniae detects and responds to foreign bacterial peptide fragments in its environment.

Hathaway LJ, Bättig P, Reber S, Rotzetter JU, Aebi S, Hauser C, Heller M, Kadioglu A, Mühlemann K.

Open Biol. 2014 Apr 9;4:130224. doi: 10.1098/rsob.130224.

42.

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.

Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S.

Breast Cancer Res Treat. 2014 Apr;144(2):321-9. doi: 10.1007/s10549-014-2849-2. Epub 2014 Feb 1.

43.

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JW, Paterson AH, Rimawi MF, Cañada JM, Thürlimann B, Murray E, Mamounas EP, Geyer CE Jr, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL; CALOR investigators.

Lancet Oncol. 2014 Feb;15(2):156-63. doi: 10.1016/S1470-2045(13)70589-8. Epub 2014 Jan 16.

44.

Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss.

Zaman K, Thuerlimann B, Aebi S.

J Clin Oncol. 2013 Sep 20;31(27):3440-1. doi: 10.1200/JCO.2013.50.9737. Epub 2013 Aug 5. No abstract available.

PMID:
23918950
45.

A patient with lung adenocarcinoma and RET fusion treated with vandetanib.

Gautschi O, Zander T, Keller FA, Strobel K, Hirschmann A, Aebi S, Diebold J.

J Thorac Oncol. 2013 May;8(5):e43-4. doi: 10.1097/JTO.0b013e31828a4d07. No abstract available.

46.
48.

16S rRNA terminal restriction fragment length polymorphism for the characterization of the nasopharyngeal microbiota.

Brugger SD, Frei L, Frey PM, Aebi S, Mühlemann K, Hilty M.

PLoS One. 2012;7(12):e52241. doi: 10.1371/journal.pone.0052241. Epub 2012 Dec 20.

49.

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, Diebold J.

J Thorac Oncol. 2012 Oct;7(10):e23-4. doi: 10.1097/JTO.0b013e3182629903. No abstract available.

50.

Transmission dynamics of extended-spectrum β-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting.

Hilty M, Betsch BY, Bögli-Stuber K, Heiniger N, Stadler M, Küffer M, Kronenberg A, Rohrer C, Aebi S, Endimiani A, Droz S, Mühlemann K.

Clin Infect Dis. 2012 Oct;55(7):967-75. doi: 10.1093/cid/cis581. Epub 2012 Jun 20.

Supplemental Content

Support Center